

<b>Indikation:</b>	<b>Studientitel:</b>	<b>Leiter klinische Prüfung:</b>	<b>Ansprechpartner:</b>
Sarkome	CWS-Register SoTiSaR: A registry for soft tissue sarcoma and other soft tissue tumours in children, adolescents, and young adults	Prof. Dr. E. Koscielniak, Olgahospital Stuttgart	Dr. med. Barbara Hermes, Tübingen
Sarkome	EWING 2008	Prof. Dr. med. Uta Dirksen, Essen	Dr. med. Barbara Hermes, Tübingen
Sarkome	COSS-Register	Prof. Dr. Bielack, Stuttgart	Dr. med. Barbara Hermes, Tübingen
Sarkome	Medisarc: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (AIO-STS-0415)	Prof. Dr. V. Grünwald, Essen	Dr. med. Barbara Hermes, Tübingen
Sarkome	NiTraSarc: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial	Dr. D. Pink, Bad Saarow	Dr. med. Barbara Hermes, Tübingen
Sarkome	POETIG trial: Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib	Prof. Dr. S. Bauer, Essen	Dr. med. Barbara Hermes, Tübingen
Sarkome	SSG XXII: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study	Dr. P. Reichardt, Berlin	Dr. med. Barbara Hermes, Tübingen

<b>Indikation:</b>	<b>Studientitel:</b>	<b>Leiter klinische Prüfung:</b>	<b>Ansprechpartner:</b>
Sarkome	TOP-ART: Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies, NCT-PMO-1603	Prof. Fröhling, Heidelberg	Dr. med. Barbara Hermes, Tübingen